Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Advanced fibre optical scanning in thin-layer chromatography for drug identification.

Ahrens B, Blankenhorn D, Spangenberg B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 May 25;772(1):11-8.

PMID:
12016011
2.

The article isn't serious.

Blankenhorn D.

Am Psychol. 2000 Jun;55(6):682-3. No abstract available.

PMID:
10892216
3.

Acid and base regulation in the proteome of Escherichia coli.

Slonczewski JL, Blankenhorn D.

Novartis Found Symp. 1999;221:75-83; discussions 83-92. Review.

PMID:
10207914
4.
5.

Proteins induced in Escherichia coli by benzoic acid.

Lambert LA, Abshire K, Blankenhorn D, Slonczewski JL.

J Bacteriol. 1997 Dec;179(23):7595-9.

6.

A glutamate-dependent acid resistance gene in Escherichia coli.

Hersh BM, Farooq FT, Barstad DN, Blankenhorn DL, Slonczewski JL.

J Bacteriol. 1996 Jul;178(13):3978-81.

7.

Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.

Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN.

Circulation. 1996 Jan 1;93(1):34-41.

PMID:
8616937
8.

Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).

Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH.

Arterioscler Thromb. 1994 Dec;14(12):1906-13.

PMID:
7981178
9.

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.

Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH.

Circulation. 1994 Jul;90(1):42-9.

PMID:
8026027
10.

Acid and base resistance in Escherichia coli and Shigella flexneri: role of rpoS and growth pH.

Small P, Blankenhorn D, Welty D, Zinser E, Slonczewski JL.

J Bacteriol. 1994 Mar;176(6):1729-37.

11.

George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal.

Blankenhorn DH, Hodis HN.

Arterioscler Thromb. 1994 Feb;14(2):177-92. Review.

PMID:
8305407
12.

One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy.

Mack WJ, Selzer RH, Hodis HN, Erickson JK, Liu CR, Liu CH, Crawford DW, Blankenhorn DH.

Stroke. 1993 Dec;24(12):1779-83.

PMID:
8248954
13.

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ; MARS Research Group.

Ann Intern Med. 1993 Nov 15;119(10):969-76.

PMID:
8214993
14.

Atherosclerosis--reversal with therapy.

Blankenhorn DH, Hodis HN.

West J Med. 1993 Aug;159(2):172-9. Review.

15.

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.

Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic P.

Circulation. 1993 Jul;88(1):20-8.

PMID:
8319334
16.

The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.

Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH.

J Rheumatol. 1993 Apr;20(4):661-5.

PMID:
8496861
17.

Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.

Blankenhorn DH, Selzer RH, Mack WJ, Crawford DW, Pogoda J, Lee PL, Shircore AM, Azen SP.

Circulation. 1992 Dec;86(6):1701-9.

PMID:
1451241
18.

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.

Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, Blankenhorn DH.

Arterioscler Thromb. 1992 Mar;12(3):348-56.

PMID:
1547194
19.

pH dependence and gene structure of inaA in Escherichia coli.

White S, Tuttle FE, Blankenhorn D, Dosch DC, Slonczewski JL.

J Bacteriol. 1992 Mar;174(5):1537-43.

20.

A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.

Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, et al.

Arterioscler Thromb. 1992 Jan;12(1):120-34. Review. No abstract available.

PMID:
1731855
21.

A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.

Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, et al.

Circulation. 1992 Jan;85(1):391-405. Review. No abstract available.

PMID:
1728483
22.

Regression of atherosclerosis: which components regress and what influences their reversal.

Kramsch DM, Blankenhorn DH.

Wien Klin Wochenschr. 1992;104(1):2-9. Review.

PMID:
1546480
23.
24.

Arterial wall oxygenation, oxyradicals, and atherosclerosis.

Crawford DW, Blankenhorn DH.

Atherosclerosis. 1991 Aug;89(2-3):97-108. Review.

PMID:
1793456
25.

Fat and cholesterol intake of attendees at two national USA cardiovascular annual meetings.

Selzer RH, Dubois-Blowers L, Darnall CJ, Azen SP, Blankenhorn DH.

Am J Cardiol. 1991 May 15;67(13):1090-6.

PMID:
2024599
26.

Relationship of arterial wall uptake of radiolabeled liposomes to the presence of monocyte/macrophage cells in the hypertensive and atherosclerotic arterial wall.

Hodis HN, Amartey JK, Crawford DW, Wickham E, Sharma RC, Blankenhorn DH.

Atherosclerosis. 1991 Apr;87(2-3):109-17.

PMID:
1854358
27.

Evaluation of human panelists in assessing coronary atherosclerosis.

Azen SP, Cashin-Hemphill L, Pogoda J, Mack WJ, Sanmarco ME, Wickham E, Blankenhorn DH.

Arterioscler Thromb. 1991 Mar-Apr;11(2):385-94.

PMID:
1998656
28.

Regression of atherosclerosis: what does it mean?

Blankenhorn DH.

Am J Med. 1991 Feb 21;90(2A):42S-47S.

PMID:
1994715
29.

Effects of colestipol-niacin therapy on human femoral atherosclerosis.

Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC.

Circulation. 1991 Feb;83(2):438-47.

PMID:
1991366
30.

Treating serum lipid abnormalities in high-priority patients.

Blankenhorn DH, Hodis HN.

Postgrad Med. 1991 Jan;89(1):81-2, 87-90, 93-6. Review.

PMID:
1985320
31.

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.

Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH.

JAMA. 1990 Dec 19;264(23):3013-7.

PMID:
2243429
32.

[Can atherosclerotic lesions regress? Angiographic demonstrations in humans].

Blankenhorn DH.

G Ital Cardiol. 1990 Nov;20(11):1085-7. Review. Italian. No abstract available.

PMID:
2090555
34.

In vivo hypertensive arterial wall uptake of radiolabeled liposomes.

Hodis HN, Amartey JK, Crawford DW, Wickham E, Blankenhorn DH.

Hypertension. 1990 Jun;15(6 Pt 1):600-5.

PMID:
2347622
35.

The influence of diet on the appearance of new lesions in human coronary arteries.

Blankenhorn DH, Johnson RL, Mack WJ, el Zein HA, Vailas LI.

JAMA. 1990 Mar 23-30;263(12):1646-52.

PMID:
2407875
36.

Can atherosclerotic lesions regress? Angiographic evidence in humans.

Blankenhorn DH.

Am J Cardiol. 1990 Mar 20;65(12):41F-43F.

PMID:
2316477
37.

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP.

Circulation. 1990 Feb;81(2):470-6.

PMID:
2404631
38.

[Determination of potentially atherogenic triglyceride-rich lipoprotein particles].

Alaupovic P, Blankenhorn DH.

Klin Wochenschr. 1990;68 Suppl 22:38-42. Review. German.

PMID:
2087077
39.

AHA Conference Report on Cholesterol. Intervention studies.

Levy RI, Blankenhorn D, Davis CE, Gordon DJ, Furberg C, Huttunen J, Levine RJ, Passamani E, Yusuf S.

Circulation. 1989 Sep;80(3):739-43. Review. No abstract available.

PMID:
2670325
40.

Prevention or reversal of atherosclerosis: review of current evidence.

Blankenhorn DH.

Am J Cardiol. 1989 May 2;63(16):38H-41H. Review.

PMID:
2650523
41.

Regression of atherosclerosis: dietary and pharmacologic approach.

Blankenhorn DH.

Can J Cardiol. 1989 May;5(4):206-10. Review.

PMID:
2659149
42.

Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical trials. A sampling study.

Selzer RH, Hagerty C, Azen SP, Siebes M, Lee P, Shircore A, Blankenhorn DH.

J Clin Invest. 1989 Feb;83(2):520-6.

43.

Angiographic assessment of atherosclerosis during lipid-lowering therapy.

Blankenhorn DH.

Cardiology. 1989;76 Suppl 1:75-9; discussion 79-82. Review. No abstract available.

PMID:
2653625
44.

Reversal of atherosis and sclerosis. The two components of atherosclerosis.

Blankenhorn DH, Kramsch DM.

Circulation. 1989 Jan;79(1):1-7. Review.

PMID:
2642753
45.

Quantitative ultrasound pulsation study in human carotid artery disease.

Barth JD, Blankenhorn DH, Wickham E, Lai JY, Chin HP, Selzer RH.

Arteriosclerosis. 1988 Nov-Dec;8(6):778-81.

PMID:
3058103
46.

Ultrasound observation on pulsation in human carotid artery lesions.

Blankenhorn DH, Chin HP, Conover DJ, Nessim SA.

Ultrasound Med Biol. 1988;14(7):583-7.

PMID:
3059647
47.

The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.

Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH.

Control Clin Trials. 1987 Dec;8(4):356-87.

PMID:
3327654
48.

A computerized quantitative food frequency analysis for the clinical setting: use in documentation and counseling.

Vailas LI, Blankenhorn DH, Johnson RL, Selzer RH.

J Am Diet Assoc. 1987 Nov;87(11):1539-43.

PMID:
3668130
49.

Alterations in serum thyroid hormonal indices with colestipol-niacin therapy.

Cashin-Hemphill L, Spencer CA, Nicoloff JT, Blankenhorn DH, Nessim SA, Chin HP, Lee NA.

Ann Intern Med. 1987 Sep;107(3):324-9.

PMID:
3113309
50.

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L.

JAMA. 1987 Jun 19;257(23):3233-40. Erratum in: JAMA 1988 May 13;259(18):2698.

PMID:
3295315

Supplemental Content

Loading ...
Support Center